Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.78 |
| ▸ | DRD3 | P35462 | 3/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.78 |
| ▸ | HRH1 | P35367 | 3/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.78 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.78 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.78 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.78 |
| ▸ | HRH2 | P25021 | 2/20 | 0.78 |
| ▸ | HTR2A | P28223 | 2/20 | 0.78 |
| ▸ | HTR2C | P28335 | 2/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenhydramine SCHEMBL12543374 | 0.88 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL4064 | 0.88 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL11795332 | 0.87 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL29205078 | 0.87 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| SCHEMBL4670285 | 0.87 | SCN1A (0.55) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL25219551 | 0.87 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL10487818 | 0.87 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL9565209 | 0.87 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL17071 | 0.87 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL28210970 | 0.87 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8026285-B2 | Control release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-09-27 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | SALEHANI FOAD | 2005-12-22 | — | — | US | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | HRH3, HRH4, HNMT | SLC6A2 641/4885SLC6A4 558/4885SLC6A3 1630/4885 |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | SLC6A2 4524/4885SLC6A4 4418/4885SLC6A3 4221/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | SLC6A2 98/4885SLC6A4 264/4885SLC6A3 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.